Galit Denkberg

1.4k total citations
21 papers, 959 citations indexed

About

Galit Denkberg is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Galit Denkberg has authored 21 papers receiving a total of 959 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Immunology, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Galit Denkberg's work include T-cell and B-cell Immunology (12 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (10 papers). Galit Denkberg is often cited by papers focused on T-cell and B-cell Immunology (12 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (10 papers). Galit Denkberg collaborates with scholars based in Israel, United States and United Kingdom. Galit Denkberg's co-authors include Yoram Reiter, Cyril J. Cohen, Avital Lev, Hennie R. Hoogenboom, Patrick Chames, Eynav Klechevsky, Yael Elbaz‐Alon, Karl Skorecki, Maty Tzukerman and Mariolina Salio and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and The Journal of Immunology.

In The Last Decade

Galit Denkberg

21 papers receiving 945 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Galit Denkberg Israel 15 745 448 272 259 80 21 959
Lindsay L. Jones United States 14 604 0.8× 393 0.9× 120 0.4× 218 0.8× 62 0.8× 20 895
Steven M. Dunn Switzerland 13 605 0.8× 618 1.4× 186 0.7× 238 0.9× 55 0.7× 25 923
Michaël Hebeisen Switzerland 14 718 1.0× 601 1.3× 88 0.3× 329 1.3× 71 0.9× 24 1.0k
Even Walseng United States 11 353 0.5× 290 0.6× 109 0.4× 269 1.0× 86 1.1× 19 716
Rodrigo Vazquez-Lombardi Australia 14 377 0.5× 221 0.5× 359 1.3× 359 1.4× 73 0.9× 17 846
Alexander V. Taranin Russia 17 608 0.8× 232 0.5× 280 1.0× 238 0.9× 43 0.5× 73 910
Michael Schwenkert Germany 13 422 0.6× 368 0.8× 221 0.8× 265 1.0× 48 0.6× 14 673
Yannick Bulliard United States 10 581 0.8× 546 1.2× 143 0.5× 205 0.8× 48 0.6× 18 914
Thomas Van Blarcom United States 15 222 0.3× 239 0.5× 421 1.5× 503 1.9× 79 1.0× 27 814
Daniel Hirschhorn-Cymerman United States 15 1.4k 1.8× 979 2.2× 74 0.3× 272 1.1× 42 0.5× 22 1.7k

Countries citing papers authored by Galit Denkberg

Since Specialization
Citations

This map shows the geographic impact of Galit Denkberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Galit Denkberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Galit Denkberg more than expected).

Fields of papers citing papers by Galit Denkberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Galit Denkberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Galit Denkberg. The network helps show where Galit Denkberg may publish in the future.

Co-authorship network of co-authors of Galit Denkberg

This figure shows the co-authorship network connecting the top 25 collaborators of Galit Denkberg. A scholar is included among the top collaborators of Galit Denkberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Galit Denkberg. Galit Denkberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horev, Guy, et al.. (2021). Phenotypic Models of CAR T-Cell Activation Elucidate the Pivotal Regulatory Role of CAR Downmodulation. Molecular Cancer Therapeutics. 20(5). 946–957. 13 indexed citations
2.
Horev, Guy, Galit Denkberg, Yael Elbaz‐Alon, et al.. (2021). Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response. Molecular Cancer Therapeutics. 20(5). 872–884. 34 indexed citations
3.
Thomas, Sharyn, Dan Blat, Galit Denkberg, et al.. (2014). Functional Comparison of Engineered T Cells Carrying a Native TCR versus TCR-like Antibody–Based Chimeric Antigen Receptors Indicates Affinity/Avidity Thresholds. The Journal of Immunology. 193(11). 5733–5743. 103 indexed citations
4.
Bronner, Vered, et al.. (2010). Therapeutic antibodies: Discovery and development using the ProteOn XPR36 biosensor interaction array system. Analytical Biochemistry. 406(2). 147–156. 16 indexed citations
5.
6.
Denkberg, Galit, Paola Pittoni, Dawn Shepherd, et al.. (2008). Phage display‐derived recombinant antibodies with TCR‐like specificity against α‐galactosylceramide and its analogues in complex with human CD1d molecules. European Journal of Immunology. 38(3). 829–840. 14 indexed citations
7.
Klechevsky, Eynav, Galit Denkberg, Karolina Palucka, et al.. (2008). Antitumor Activity of Immunotoxins with T-Cell Receptor–like Specificity against Human Melanoma Xenografts. Cancer Research. 68(15). 6360–6367. 43 indexed citations
8.
McCarthy, Corinna, Dawn Shepherd, Sebastian J. Fleire, et al.. (2007). The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. The Journal of Experimental Medicine. 204(5). 1131–1144. 184 indexed citations
9.
Oved, Kfir, Omer Ziv, Jasmine Jacob‐Hirsch, et al.. (2007). A Novel Postpriming Regulatory Check Point of Effector/Memory T Cells Dictated through Antigen Density Threshold-Dependent Anergy. The Journal of Immunology. 178(4). 2307–2317. 14 indexed citations
10.
Noy, Roy, et al.. (2005). T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy. Expert Review of Anticancer Therapy. 5(3). 523–536. 13 indexed citations
11.
Denkberg, Galit & Yoram Reiter. (2005). Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation. Autoimmunity Reviews. 5(4). 252–257. 29 indexed citations
12.
Denkberg, Galit, Avital Lev, Lea Eisenbach, Itai Benhar, & Yoram Reiter. (2003). Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen. The Journal of Immunology. 171(5). 2197–2207. 49 indexed citations
13.
14.
Cohen, Cyril J., et al.. (2003). Simultaneous monitoring of binding to and activation of tumor-specific T lymphocytes by peptide–MHC. Journal of Immunological Methods. 277(1-2). 39–52. 9 indexed citations
15.
Cohen, Cyril J., et al.. (2003). Generation of Recombinant Immunotoxins for Specific Targeting of Tumor-Related Peptides Presented by MHC Molecules. Humana Press eBooks. 207. 269–282. 9 indexed citations
16.
Denkberg, Galit, Eynav Klechevsky, & Yoram Reiter. (2002). Modification of a Tumor-Derived Peptide at an HLA-A2 Anchor Residue Can Alter the Conformation of the MHC-Peptide Complex: Probing with TCR-Like Recombinant Antibodies. The Journal of Immunology. 169(8). 4399–4407. 40 indexed citations
17.
Lev, Avital, Galit Denkberg, Cyril J. Cohen, et al.. (2002). Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.. PubMed. 62(11). 3184–94. 88 indexed citations
18.
Denkberg, Galit, Cyril J. Cohen, & Yoram Reiter. (2001). Critical Role for CD8 in Binding of MHC Tetramers to TCR: CD8 Antibodies Block Specific Binding of Human Tumor- Specific MHC-Peptide Tetramers to TCR. The Journal of Immunology. 167(1). 270–276. 68 indexed citations
19.
Denkberg, Galit, et al.. (2001). Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins. Current Pharmaceutical Biotechnology. 2(1). 19–46. 15 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lindsay L. Jones Breakdown of academic impact, for papers by Steven M. Dunn Breakdown of academic impact, for papers by Michaël Hebeisen Breakdown of academic impact, for papers by Even Walseng Breakdown of academic impact, for papers by Rodrigo Vazquez-Lombardi Breakdown of academic impact, for papers by Alexander V. Taranin Breakdown of academic impact, for papers by Michael Schwenkert Breakdown of academic impact, for papers by Yannick Bulliard Breakdown of academic impact, for papers by Thomas Van Blarcom Breakdown of academic impact, for papers by Daniel Hirschhorn-Cymerman
Rankless by CCL
2026